BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24792499)

  • 21. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.
    Chow R; Valdez C; Chow N; Zhang D; Im J; Sodhi E; Lock M
    Support Care Cancer; 2020 May; 28(5):2095-2103. PubMed ID: 31916006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ondansetron: a review of its use as an antiemetic in children.
    Culy CR; Bhana N; Plosker GL
    Paediatr Drugs; 2001; 3(6):441-79. PubMed ID: 11437189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence.
    Chasen MR; Rapoport BL
    Future Oncol; 2016 Mar; 12(6):763-78. PubMed ID: 26842387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
    Shih V; Wan HS; Chan A
    Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
    Pendergrass K; Hargreaves R; Petty KJ; Carides AD; Evans JK; Horgan KJ
    Drugs Today (Barc); 2004 Oct; 40(10):853-63. PubMed ID: 15605119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.
    Tan M
    Expert Opin Pharmacother; 2003 Sep; 4(9):1563-71. PubMed ID: 12943486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Experience with aprepitant in the prevention of nausea and vomiting caused by highly emetic chemotherapy of lung cancer].
    Tamási L; Müller V; Magyar P
    Magy Onkol; 2008 Jun; 52(2):179-83. PubMed ID: 18640894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aprepitant in the prevention of vomiting induced by moderately and highly emetogenic chemotherapy.
    Wang SY; Yang ZJ; Zhang Z; Zhang H
    Asian Pac J Cancer Prev; 2014; 15(23):10045-51. PubMed ID: 25556423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2015; 15(10):1127-33. PubMed ID: 26366937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing Nausea and Vomiting in Patients With Cancer: What Works.
    Navari RM
    Oncology (Williston Park); 2018 Mar; 32(3):121-5, 131, 136. PubMed ID: 29548068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical usefulness of ondansetron hydrochloride for nausea and vomiting during repeated courses of chemotherapy for malignant lymphoma--impact of prognosis announcement on anti-emetic effect and evaluation of patient perception of chemotherapy-associated adverse events].
    Kodama F; Mohri H; Motomura S; Fukawa H; Tanabe J; Koharasawa H; Kanamori H; Hashimoto Y; Harano H; Sakai R; Tomita N; Fujimaki K; Takemura S; Hattori M
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):273-9. PubMed ID: 11865634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
    Longo F; Mansueto G; Lapadula V; De Sanctis R; Quadrini S; Grande R; Gori B; Altavilla A; D'Antoni I; Del Signore E; Stumbo L; De Luca C; Cimadon B; Cortesi E; Gamucci T; Di Seri M
    Support Care Cancer; 2011 Aug; 19(8):1159-64. PubMed ID: 20552375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aprepitant: a review of its use in the prevention of nausea and vomiting.
    Curran MP; Robinson DM
    Drugs; 2009; 69(13):1853-78. PubMed ID: 19719336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
    Abdel-Malek R; Abbas N; Shohdy KS; Ismail M; Fawzy R; Salem DS; Safwat E
    J Egypt Natl Canc Inst; 2017 Sep; 29(3):155-158. PubMed ID: 28844591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.